Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 6262-year-old man is evaluated prior to hospital discharge following an admission for acute decompensated heart failure. He has a history of ischemic cardiomyopathy with a left ventricular ejection fraction of 25%25\%. His home medications prior to admission included lisinopril, carvedilol, and furosemide. During the hospital stay, he was appropriately diuresed to euvolemia. The medical team plans to optimize his guideline-directed medical therapy by discontinuing lisinopril, initiating sacubitril-valsartan, and adding spironolactone. His vital signs are currently stable. Laboratory results obtained this morning show a serum potassium of 4.24.2 mEq/L and an estimated glomerular filtration rate (eGFR) of 5555 mL/min/1.73 m 2^2. Which of the following statements regarding the monitoring and modification of this patient's pharmacotherapy are correct? (Select all that apply)

  1. A strict 3636-hour washout period is required between the final dose of the ACE inhibitor and the first dose of the angiotensin receptor-neprilysin inhibitor.Cevap
  2. A basic metabolic panel must be re-evaluated within 11 to 22 weeks following discharge to assess for renal dysfunction and electrolyte abnormalities.Cevap
  3. C
    Therapeutic volume status and response should be longitudinally monitored using serial serum B-type natriuretic peptide (BNP) levels.
  4. D
    The mineralocorticoid receptor antagonist should be titrated to the maximum tolerated dose even if subsequent serum potassium levels rise to 5.85.8 mEq/L.
  5. E
    A repeat transthoracic echocardiogram should be ordered 22 to 33 weeks post-discharge to document early ventricular reverse remodeling.

Cevap

The correct statements are that a 36-hour washout period is required between lisinopril and sacubitril-valsartan, and that a basic metabolic panel must be re-evaluated within 1 to 2 weeks of discharge.
The successful and safe implementation of comprehensive guideline-directed medical therapy for HFrEF requires meticulous monitoring. First, when transitioning a patient from an ACE inhibitor (such as lisinopril) to an angiotensin receptor-neprilysin inhibitor (ARNI, such as sacubitril-valsartan), a strict 36-hour washout period is mandatory. Both drugs prevent the breakdown of bradykinin; concurrent use or insufficient clearance can lead to life-threatening angioedema. Second, the simultaneous initiation of an ARNI and a mineralocorticoid receptor antagonist (spironolactone) places the patient at high risk for hyperkalemia and acute kidney injury. Current guidelines mandate re-evaluating renal function and serum potassium within 1 to 2 weeks following initiation or dose adjustments of these medications.

Adım Adım Çözüm

1
Identify the patient's new therapeutic regimen and recent medication changes.
The patient is transitioning from lisinopril (an ACE inhibitor) to sacubitril-valsartan (an ARNI) and is starting spironolactone (an MRA).
Recognizing the specific classes of medications is necessary to anticipate adverse effects, drug interactions, and required monitoring parameters.
2
Determine the safety protocols for transitioning to an ARNI.
A strict 36-hour washout period is identified as a necessary step before starting sacubitril-valsartan after an ACE inhibitor.
Both ACE inhibitors and sacubitril increase bradykinin levels. Overlapping their effects poses a severe risk for angioedema.
3
Determine the laboratory monitoring required for the new regimen.
Checking a basic metabolic panel within 1 to 2 weeks is identified as necessary.
Both ARNIs and MRAs independently reduce aldosterone signaling and affect renal hemodynamics, creating a high risk for hyperkalemia and acute kidney injury shortly after initiation.
4
Evaluate the distractors against standard monitoring timelines and assay interferences.
Serial BNP is inaccurate in patients on sacubitril. Potassium levels of 5.8 mEq/L are a contraindication for MRA titration. Echocardiography at 2-3 weeks is premature.
Sacubitril inhibits BNP degradation. Potassium > 5.5 mEq/L requires holding the MRA. Ventricular remodeling takes 3 to 6 months.

Anahtar Kavram

Monitoring and transitioning guideline-directed medical therapy in heart failure with reduced ejection fraction (HFrEF).
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru